On the heels of a groundbreaking FDA approval for a major medtech, a Silicon Valley startup is shaping up to be a possible ...

The rare, deadly blood clots triggered by an autoimmune response to the COVID-19 vaccines from Johnson & Johnson and ...

Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while ...

Atai Life Sciences, one of the leading shareholders in psilocybin drug developer Compass Pathways, is swapping CEOs.

The FDA has approved two diagnostic devices that allow women to collect vaginal samples themselves for cervical cancer ...

Thermo Fisher Scientific has put forward a DNA-based test it says can offer much more precise identification of blood and its ...

Johnson & Johnson is shelling out $850 million to buy Proteologix, getting hold of a young roster of bispecific immunology ...

Results from the phase 3 SUPERNOVA study show that the company’s investigational long-acting antibody (LAA) sipavibart ...

Health has gathered $25 million in funding to help continue clinical studies of its less invasive, outpatient procedure for ...

After picking up $100 million in venture capital cash earlier this month, Karius is adding another feather to its cap with a ...

What a time to be launching a new biotech focused on inflammation and immunology. | Immunology and inflammation-focused drug ...

Sanofi is betting $80 million upfront on a GSK castoff ahead of a phase 3 readout. Fulcrum Therapeutics took the other side ...